©2024 Stanford Medicine
Cardiac Safety Study of Brentuximab Vedotin (SGN-35)
Not Recruiting
Trial ID: NCT01026233
Purpose
The purpose of this study is to evaluate cardiac safety of brentuximab vedotin (SGN-35) in
patients with CD30-positive cancers. The study will assess electrical activity of the heart
before and after brentuximab vedotin administration. Patients who have stable or improving
disease may receive up to 1 year of brentuximab vedotin treatment.
Official Title
An Intensive QT/QTc Study to Investigate the Effects of SGN-35 (Brentuximab Vedotin) on Cardiac Ventricular Repolarization in Patients With CD30-Positive Malignancies
Eligibility
Inclusion Criteria:
- Relapsed or refractory CD30-positive malignancy
- Adequate organ function
- ECOG performance status <2
Exclusion Criteria:
- Cardiac abnormalities (abnormal rhythm, history of significant cardiac event)
- Current diagnosis of primary cutaneous ALCL
- Acute or chronic graft-versus-host disease
- Prior hematopoietic stem cell transplant within specified timeframe
Intervention(s):
drug: Brentuximab vedotin
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cancer Clinical Trials Office
650-498-7061